Observation on the effect of chemotherapy combined with gefitinib small molecule targeted therapy for patients with advanced lung cancer and its influence on serum CYFRA21-1
Objective To explore the effect of chemotherapy combined with gefitinib small molecule targeted therapy for patients with advanced lung cancer and its influence on serum cytokeratin 19 fragments antigen 21-1(CYFRA21-1).Methods 106 patients with advanced lung cancer were divided into a control group(53 cases)and an observation group(53 cases)according to the difference of treatment regimen.The control group was treated with chemotherapy,and the observation group was treated with chemotherapy and gefitinib small molecule targeted therapy.Both groups were compared in terms of clinical efficacy and serum inflammatory factors(interleukin-6,interleukin-8,interleukin-1β),serum tumor markers[CYFRA21-1,carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)],lung function(ratio of forced expiratory volume in one second to forced vital capacity,maximum ventilation volume,maximum mid-expiratory flow),quality of life before and after treatment.Results The clinical remission rate of the observation group was significantly higher than that of the control group(86.79%VS 66.04%,P<0.05).Compared with this group before treatment,the levels of interleukin-6,interleukin-8 and interleukin-1β in both groups decreased after treatment;after treatment,the observation group had interleukin-6 of(60.78±5.30)pg/ml,interleukin-8 of(73.86±10.02)pg/ml and interleukin-1β of(58.57±20.51)pg/ml,which were lower than(67.82±4.03),(86.78±9.34)and(71.96±25.11)pg/ml in the control group(P<0.05).Compared with this group before treatment,the levels of CYFRA21-1,CA125 and CA199 in both groups decreased after treatment;after treatment,the observation group had CYFRA21-1 of(8.47±1.09)μg/L,CA125 of(38.43±5.12)kU/L and CA199 of(40.23±6.16)kU/L,which were lower than(12.58±1.33)μg/L,(50.67±3.49)kU/L and(58.40±7.75)kU/L in the control group(P<0.05).Compared with this group before treatment,the ratio of forced expiratory volume in one second to forced vital capacity,maximum ventilation volume,maximum mid-expiratory flow increased in both groups after treatment,and the observation group was higher than the control group(P<0.05).Compared with this group before treatment,the scores of appetite loss,shortness of breath,cough,fatigue,pain and blood in sputum all decreased in both group after treatment,and the observation group was lower than the control group(P<0.05).Conclusion Chemotherapy combined with gefitinib small molecule targeted therapy for advanced lung cancer can improve the clinical efficacy of patients,reduce the levels of serum inflammatory factors and related tumor markers,and further improve lung function.
NETL
NSTL
万方数据
